世界中西医结合杂志2025，Vol.20Issue(6)：1061-1073,13.DOI:10.13935/j.cnki.sjzx.250601
口服中成药辅助治疗H型高血压的网状Meta分析
Network Meta-analysis of Oral Chinese Patent Medicines in the Adjunctive Treat-ment of H-type Hypertension
摘要
Abstract
Objective To evaluate the efficacy and safety of different varieties of oral Chinese patent medicines in the adjunctive treatment of H-type hypertension using network Meta-analysis.Methods Randomized controlled trials(RCTs)on the treatment of H-type hypertension with Chinese patent medicines were searched on PubMed,Cochrane Li-brary,EMbase,Web of Science,Wanfang Data,VIP,CNKI,and SinoMed.The RevMan 5.3 and Stata 16.0 software were used for Meta-analysis,and the Cochrane risk of bias tool was employed to evaluate the quality of the literature retrieved.Results Thirty RCTs were included,involving 11 oral Chinese patent medicines such as Songling Xuemaikang capsule and Tongxinluo capsule.Network meta-analysis showed that,when combined with conventional Western medicine,the Qiangli Dingxuan tablet was the most clinically efficient,the Qishen Yiqi dropping pill was the best in reducing diastolic blood pres-sure(DBP)and homocysteine(Hcy),Huanglian Shangqing pill was the best in reducing systolic blood pressure(SBP),and Qili Qiangxin capsule was the safest.According to the result of the comprehensive efficacy analysis,the Huanglian Shangqing pill or Qishen Yiqi dropping pill combined with conventional Western medicine was preferred for the clinical treatment of H-type hypertension.Conclusion The oral Chinese patent medicines in the adjunctive treatment of H-type hypertension can improve clinical efficiency and reduce blood pressure and homocysteine in patients,with a relatively high safety profile.In the clinical treatment of H-type hypertension,Huanglian Shangqing pill or Qishen Yiqi dropping pill combined with conven-tional Western medicine may be preferred.However,the therapeutic recommendations obtained in this study still need to be adopted with caution.Besides,further verification of the conclusions is still needed by more high-quality RCTs.关键词
中成药/H型高血压/网状Meta分析/随机对照试验/循证评价Key words
Chinese Patent Medicine/H-type Hypertension/Network Meta-analysis/Randomized Controlled Trials/Evidence-based Evaluation分类
医药卫生引用本文复制引用
于宗良,于滨洋,丰雪,李灵凌,高蕊..口服中成药辅助治疗H型高血压的网状Meta分析[J].世界中西医结合杂志,2025,20(6):1061-1073,13.基金项目
国家重点研发计划(2021YFF0901404) （2021YFF0901404）
中国中医科学院科技创新工程(CI2021A04701) （CI2021A04701）
